Moderate doses of statins and combination of statin with ezetimibe in patients with carotide atherosclerosis: influence on blood lipids, inflammation markers and thickness of intima-media complex


Cite item

Full Text

Abstract

We investigated the effects of low doses of simvastatin (original and generic products in the average daily dose of 18 mg), atorvastatin (13 mg/day), rosuvastatin (11 mg/day) and simvastatin (12 mg/day) in combination with ezetimibe (10 mg/day) in patients with carotid atherosclerosis without marked hyperlipidemia. We assessed lipid levels, levels of markers of inflammation, and the thickness of the intima-media complex (IMT) according to duplex ultrasonography screening of brachycephalic arteries. Within 36 weeks 180 patients were observed. 150 patients received active treatment, 30 entered in control group. Treatment with low doses of statins and the use of a combination of simvastatin with ezetimibe led to decrease of low density lipoprotein cholesterol levels by at least 30% that led to the achievement of the target values in some patients. Most hypolipodemic effect was achieved against the background of combination of simvastatin and ezetimibe, and monotherapy with rosuvastatin. The level of C-reactive protein in the blood against the background of monotherapy with statins has not changed, and in the group of combination therapy with simvastatin and ezetimibe was significantly reduced. Treatment with low doses of statins, and combination of simvastatin with ezetimibe did not lead to significant change of IMT, indicating inhibition of the atherosclerosis progression, whereas IMT in the control group was significantly increased.

References

  1. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis or data from 90,056 participants in 14 randommised trials of statins. Lancet 2005;366:1267-78.
  2. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84.
  3. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008;359:2195-207.
  4. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7.
  5. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial. JAMA 2004;291:1071-80.
  6. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial. JAMA 2006;295
  7. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med 2008;358:1431-43.
  8. Bots M, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: a Rotterdam Study. Circulation 1997;96:1432-7.
  9. Hodis H, Mack WJ, LaBree L, et al. The role of carotid intima-media thickness in predicting clinical coronary events. An intern Med 1998;128:262-9.
  10. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87.
  11. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996;124:548-6.
  12. Taylor AJ, Kent SM, Flaherty PJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
  13. Crouse III JR, Raichlen JS, Riley WA, et al. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. The METEOR Trial. JAMA 2007;297:1344-53.
  14. Сусеков А.В., Зубарева М.Ю., Деев А.Д и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MMS) // Сердце. 2006. № 5. C. 324-328.
  15. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389-99.
  16. Gotto AM, Opie LH. Lipid-Modifying Antiatherosclerotic drugs. In: Drugs for the Heart. Eds. Opie L.H., Gersh B.J. 7th Ed., Eslevier Saunders 2009;341-72.
  17. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. 2009 N Engl J Med 2009;361.
  18. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2566&mid=1085056570&magid=189

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies